glp 1 gip agonists Understand GLP-1/GIP Dual Agonist Tirzepatide and Its Effect on Current Weight Loss Therapy GLP1 agonists: current and future

Calvin Scott Inc

Latest U.S

Two common problems stand out

In the two-year STEP 5 study, 77.1% of participants lost at least 5% of their body weight , and 36.1% achieved a reduction of 20% or more

An inverse correlation is observed between plasma PYY and BMD in populations with weight gain and obesity (decreased PYY and increased BMD) and in weight loss scenarios (increased PYY and decreased BMD), as observed in patients with anorexia and amenorrheic athletes [81]

The study titled Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice and published in Hormone and Metabolic Research indicates that 58% of patients reported side effects mostly concerning the gastrointestinal tract. In addition, more than 20% of the participants quit the drug because of intolerable side effects. This study certainly put Novo Nordisk on risk of bowel injuries associated with the use of Ozempic